In vitro and in vivo anti-retroviral activity of the substance purified from the aqueous extract of Chelidonium majus L.

Antiviral Research

Volumn 72, Issue 2, 2006, Pages 153-156

  Gerenčer, Marijan ^a   Turecek, Peter L ^a   Kistner, Otfried ^a   Mitterer, Artur ^a   Savidis Dacho, Helga ^a   Barrett, Noel P ^a  

^a BAXTER INNOVATIONS GMBH   (Austria)

Author keywords

Chelidonium; Glycosaminoglycans; HIV 1 inhibition; MAIDS; Retroviruses

Indexed keywords

AMINOACRIDINE; ANTIRETROVIRUS AGENT; CHELIDONIUM EXTRACT; GAG PROTEIN; GLYCOSAMINOGLYCAN; PHENOL; RNA DIRECTED DNA POLYMERASE; SULFURIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CELL SPREADING; CERVICAL LYMPH NODE; CHELIDONIUM; CHRONIC DISEASE; CONTROLLED STUDY; GEL FILTRATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ION EXCHANGE CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR WEIGHT; MOUSE; MURINE LEUKEMIA VIRUS; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; PROTEIN PURIFICATION; SPLENOMEGALY; SULFATION;

ANIMALS; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CHELIDONIUM; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, ION EXCHANGE; DISEASE MODELS, ANIMAL; FRACTIONAL PRECIPITATION; GLYCOSAMINOGLYCANS; HIV CORE PROTEIN P24; HIV REVERSE TRANSCRIPTASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LEUKEMIA VIRUS, MURINE; MASS SPECTROMETRY; MICE; MICE, INBRED C57BL; MOLECULAR WEIGHT; PLANT EXTRACTS; RETROVIRIDAE INFECTIONS; TUMOR VIRUS INFECTIONS;

CHELIDONIUM; CHELIDONIUM MAJUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE;

EID: 33748298762     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.03.008     Document Type: Article

References (19)

1. Baba M., Schols D., Pauwels R., Nakashima H., and de Clercq E. Sulfated polysaccharides as potent inhibitors of HIV-induced syncytium formation: a new strategy towards AIDS chemotherapy. J. Acq. Immun. Def. Synd. 3 (1990) 493-499
2. Boulerice F., Bour S., Geleziunas R., Lvovich A., and Wainberg M.A. High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells. J. Virol. 64 (1990) 1745-1755
3. Bulow H.E., and Hobert O. Differential sulfations and epimerization define heparan sulfate specificity in nervous system development. Neuron 4 (2004) 723-736
4. Colombo M.L., and Bosisio E. Pharmacological activities of Chelidonium majus L. (Papaveraceae). Pharmacol. Res. 33 (1996) 127-134
5. Dubois M., Gilles K.A., Hamilton J.K., Rebers P.A., and Smith F. Colorimetric method for determination of sugars and related substances. Anal. Chem. 28 (1956) 350-356
6. Habermehl D., Kammerer B., Handrick R., Eldh T., Gruber C., Cordes N., Daniel P.T., Plasswilm L., Bamberg M., Belka C., and Jendrossek V. Proapoptotic activity of Ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathway. BMC Cancer 6 (2006) 14
7. Ito M., Nakashima H., Baba M., Pauwels R., de Clercq E., Shigeta S., and Yamamoto N. Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV (HTLV-III/LAV)]. Antivir. Res. 7 (1987) 127-137
8. Jang S.I., Kim B.H., Lee W.Y., An S.J., Choi H.G., Jeon B.H., Chung H.T., Rho J.R., Kim Y.J., and Chai K.Y. Stylopine from Chelidonium majus inhibits LPS-induced inflammatory mediators in RAW 264.7 cells. Arch. Pharm. Res. 27 (2004) 923-929
9. Liang B., Wang J.Y., and Watson R.R. Murine AIDS, a key to understanding retrovirus-induced immunodeficiency. Viral Immunol. 9 (1996) 225-239
10. Mills E., Montori V., Perri D., Phillips E., and Koren G. Natural health product-HIV drug interactions: a systematic review. Int. J. STD AIDS 16 (2005) 181-186
11. Moulard M., Lortat-Jacob H., Mondor I., Roca G., Wyatt R., Sodroski J., Zhao L., Olson W., Kwong P.D., and Sattentau Q.J. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J. Virol. 74 (2000) 1948-1960
12. Mulloy B. The specificity of interactions between proteins and sulfated polysaccharides. An. Acad. Bras. Cienc. 77 (2005) 651-664
13. Pieroni A., Dibra B., Grishaj G., Grishaj I., and Gjon Macai S. Traditional phyto-therapy of the Albanians of Lepushe, Northern Albanian Alps. Fitoterapia 76 (2005) 379-399
14. Tabba H.D., Chang R.S., and Smith K.M. Isolation, purification, and partial characterization of prunellin, an anti-HIV component from aqueous extracts of Prunella vulgaris. Antivir. Res. 11 (1989) 263-273
15. Tan G.T., Pezzuto J., Kinghorn A.D., and Hughes S.H. Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. J. Nat. Prod. 54 (1991) 143-154
16. Vives R.R., Imberty A., Sattentau Q.J., and Lortat-Jacob H. Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site. J. Biol. Chem. 280 (2005) 21353-21357
17. Vlietinck A.J., De Bruyne T., Apers S., and Pieters L.A. Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection. Planta Med. 64 (1998) 97-109
18. Yao X.-J., Wainberg M.A., and Parniak M.A. Mechanism of inhibition of HIV-1 infection in vitro by purified extract of Prunella vulgaris. Virology 187 (1992) 56-62
19. Zhang Y.-J., Hatziioannou T., Zang T., Braaten D., Luban J., Goff S.P., and Bieniasz P.D. Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J. Virol. 76 (2002) 6332-6343